Medical Affairs

---

Clinical Trials

Please click on the identifier number below to view a summary of current and past studies as posted on ClinicalTrials.gov.

XEN1101 (Epilepsy)

ClinicalTrials.gov Identifier NCT05614063: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2)

ClinicalTrials.gov Identifier NCT05716100: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

ClinicalTrials.gov Identifier NCT05667142: A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

ClinicalTrials.gov Identifier NCT05718817: An Open-label Study of XEN1101 in Epilepsy (OLE: Open-label extension of X-TOLE2, X-TOLE3, and X-ACKT studies)

Previous Studies:

ClinicalTrials.gov Identifier NCT03796962: Phase 2b Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

ClinicalTrials.gov Identifier NCT03468725: Phase 1b Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

ClinicalTrials.gov Identifier NCT03340220: Phase 1a Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN1101

XEN1101 (Major Depressive Disorder)

ClinicalTrials.gov Identifier NCT05376150: A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

ClinicalTrials.gov Identifier NCT04827901: Investigator-Led Study to Evaluate XEN1101 for Major Depressive Disorder (Icahn School of Medicine at Mount Sinai)

XEN496

ClinicalTrials.gov Identifier NCT04639310: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

NBI-921352: Partnered Program with Neurocrine Biosciences (previously XEN901) 

ClinicalTrials.gov Identifier NCT03467100: Phase 1 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901